Details for New Drug Application (NDA): 050630
✉ Email this page to a colleague
The generic ingredient in PRIMAXIN is cilastatin sodium; imipenem. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cilastatin sodium; imipenem profile page.
Summary for 050630
Tradename: | PRIMAXIN |
Applicant: | Merck |
Ingredient: | cilastatin sodium; imipenem |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAMUSCULAR | Strength | EQ 500MG BASE/VIAL;500MG/VIAL | ||||
Approval Date: | Dec 14, 1990 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAMUSCULAR | Strength | EQ 750MG BASE/VIAL;750MG/VIAL | ||||
Approval Date: | Dec 14, 1990 | TE: | RLD: | No |
Expired US Patents for NDA 050630
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-001 | Dec 14, 1990 | 5,147,868 | ⤷ Subscribe |
Merck | PRIMAXIN | cilastatin sodium; imipenem | POWDER;INTRAMUSCULAR | 050630-002 | Dec 14, 1990 | 5,147,868 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription